LU92923I2 - Une solution d'irrigation oculaire comprenant de la phényléphrine ou un sel pharmaceutiquement acceptable de celle-ci et du kétorolac ou un sel pharmaceutiquement acceptable de celui-ci - Google Patents

Une solution d'irrigation oculaire comprenant de la phényléphrine ou un sel pharmaceutiquement acceptable de celle-ci et du kétorolac ou un sel pharmaceutiquement acceptable de celui-ci Download PDF

Info

Publication number
LU92923I2
LU92923I2 LU92923C LU92923C LU92923I2 LU 92923 I2 LU92923 I2 LU 92923I2 LU 92923 C LU92923 C LU 92923C LU 92923 C LU92923 C LU 92923C LU 92923 I2 LU92923 I2 LU 92923I2
Authority
LU
Luxembourg
Prior art keywords
pharmaceutically acceptable
acceptable salt
phenylephrine
ketorolac
irrigation solution
Prior art date
Application number
LU92923C
Other languages
English (en)
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92923(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of LU92923I2 publication Critical patent/LU92923I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
LU92923C 2002-07-30 2015-12-23 Une solution d'irrigation oculaire comprenant de la phényléphrine ou un sel pharmaceutiquement acceptable de celle-ci et du kétorolac ou un sel pharmaceutiquement acceptable de celui-ci LU92923I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39989902P 2002-07-30 2002-07-30
PCT/US2003/023871 WO2004010894A2 (fr) 2002-07-30 2003-07-30 Solutions et procede d'irrigation ophtalmologique

Publications (1)

Publication Number Publication Date
LU92923I2 true LU92923I2 (fr) 2016-02-23

Family

ID=31188639

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92923C LU92923I2 (fr) 2002-07-30 2015-12-23 Une solution d'irrigation oculaire comprenant de la phényléphrine ou un sel pharmaceutiquement acceptable de celle-ci et du kétorolac ou un sel pharmaceutiquement acceptable de celui-ci

Country Status (18)

Country Link
US (10) US20040072809A1 (fr)
EP (1) EP1534313B1 (fr)
JP (11) JP2006504661A (fr)
CN (3) CN101327325A (fr)
AU (2) AU2003261304A1 (fr)
BE (1) BE2015C078I2 (fr)
CA (2) CA2866848C (fr)
CY (1) CY2015055I1 (fr)
DK (1) DK1534313T3 (fr)
ES (1) ES2397574T3 (fr)
FR (1) FR15C0090I2 (fr)
HK (1) HK1081455A1 (fr)
HU (1) HUS1500069I1 (fr)
LU (1) LU92923I2 (fr)
NL (1) NL300784I2 (fr)
PT (1) PT1534313E (fr)
SI (1) SI1534313T1 (fr)
WO (1) WO2004010894A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006504661A (ja) 2002-07-30 2006-02-09 オメロス コーポレイション 眼科学的洗浄溶液および眼科学的洗浄方法
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
US8748402B2 (en) 2004-06-07 2014-06-10 Bausch & Lomb Pharma Holdings Corp. Ophthalmic formulations and uses thereof
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
HUE032349T2 (en) 2004-06-10 2017-09-28 Omeros Corp Procedures for the treatment of conditions associated with MASP-2 dependent complement mediated activation
ATE529133T1 (de) * 2004-08-18 2011-11-15 Medrx Co Ltd Topisches präparat
FR2882930B1 (fr) * 2005-03-09 2009-03-27 Walid Katib Nouvelles compositions ophtalmologiques et leur mode d'utilisation
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery
BRPI0720434A2 (pt) * 2006-12-22 2014-01-07 Sigma Tau Ind Farmaceuti Gel útil para liberação de fármacos oftálmicos
EP2068855A2 (fr) * 2007-06-05 2009-06-17 Xenon Pharmaceuticals Inc. Composés aromatiques et hétéroaromatiques utiles dans le traitement de troubles du métabolisme du fer
CN101347620B (zh) * 2007-07-20 2012-04-25 天津药业研究院有限公司 一种药物组合物及其在制备治疗青光眼的药物中的应用
US8603497B2 (en) 2008-10-30 2013-12-10 National University Corporation Okayama University Composition for local anesthesia
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
CA2754996A1 (fr) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Formulations ophtalmiques de ketotifene et procedes d'utilisation
GB0915319D0 (en) * 2009-09-03 2009-10-07 Sharma Anant Combination medicament
RU2600876C2 (ru) 2009-10-16 2016-10-27 Омерос Корпорейшен Способ лечения диссеминированного внутрисосудистого свертывания крови путем ингибирования masp-2 зависимой активации комплемента
BR112013021048A2 (pt) * 2011-02-18 2016-10-18 M S Appasmy Associates composição oftálmica para permitir dilatação de pupilas
ITPA20110004A1 (it) * 2011-02-23 2012-08-24 Francesco Paolo Montalto Iniezione intracamerulare per anestesia e dilatazione pupillare (midriasi).
EP3287142B1 (fr) 2011-04-08 2021-08-04 University Of Leicester Méthodes de traitement d'états associés à une activation du complément dépendant de masp-2
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
RU2525512C1 (ru) * 2013-03-28 2014-08-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ медикаментозного расширения ригидного зрачка перед проведением факоэмульсификации
ES2871116T3 (es) * 2013-05-06 2021-10-28 Kaohsiung Chang Gung Memorial Hospital Composición farmacéutica de un AINE y atropina
RU2529787C1 (ru) * 2013-06-03 2014-09-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Офтальмологический ирригационный раствор
EP3035903B1 (fr) 2013-08-20 2018-08-22 Anutra Medical, Inc. Système de remplissage de seringue et procédé associé
BR112016007328A2 (pt) * 2013-10-03 2017-08-01 Imprimis Pharmaceuticals Inc composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas
US10981951B2 (en) 2014-01-31 2021-04-20 Mayo Foundation For Medical Education And Research Therapeutics for the treatment of glaucoma
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
CN104324049A (zh) * 2014-09-26 2015-02-04 浙江天瑞药业有限公司 一种制备关节手术用平衡盐冲洗液的方法
TWI809304B (zh) * 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CN104856990A (zh) * 2015-05-07 2015-08-26 武汉武药科技有限公司 去氧肾上腺素酮咯酸溶液及制备方法
CN105213418B (zh) * 2015-11-11 2019-01-22 中国人民解放军第四军医大学 一种眼科术前用复方滴眼液及其制备方法
US10220012B2 (en) * 2016-06-03 2019-03-05 Joerg H. KRUMEICH Solution for ophthalmology
US10231968B2 (en) 2016-08-01 2019-03-19 David R. Hardten Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies
AU2017315757A1 (en) 2016-08-25 2019-03-07 Harrow Ip, Llc Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
EP4316595A3 (fr) * 2016-09-02 2024-04-17 Christopher J. Soares Utilisation d'antagonistes du récepteur cgrp pour le traitement du glaucome
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
CN107137713A (zh) * 2017-05-12 2017-09-08 浙江工贸职业技术学院 一种眼科手术后用冲洗液及其制备方法
MX2019014748A (es) * 2017-06-08 2020-08-03 Eye Therapies Llc Combinaciones de brimonidina de dosis baja y usos de las mismas.
EP3706868A4 (fr) * 2017-11-10 2021-12-15 The Regents of the University of Colorado, a Body Corporate Procédés d'induction d'une dilatation pupillaire
SG11202010472XA (en) 2018-04-24 2020-11-27 Allergan Inc Use of pilocarpine hydrochloride for the treatment of ocular conditions
KR20240027865A (ko) 2019-03-11 2024-03-04 닛폰 호소 교카이 화상 부호화 장치, 화상 복호 장치 및 프로그램
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
CA3166579A1 (fr) * 2020-02-07 2021-08-12 Qlaris Bio, Inc. Methodes et compositions ameliorees de therapie de promedicament de cromakalim
US11793789B2 (en) 2021-07-23 2023-10-24 Somerset Therapeutics, Llc Treatment of ophthalmological conditions using buffer-free ophthalmological compositions of ketorolac and phenylephrine
US12029729B2 (en) 2021-07-23 2024-07-09 Somerset Therapeutics, Llc Chelated, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof
WO2023048174A1 (fr) * 2021-09-22 2023-03-30 テイカ製薬株式会社 Agent thérapeutique pour maladie de la cornée

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
WO1987007141A1 (fr) 1986-05-23 1987-12-03 New England Medical Center Hospitals, Inc. Methode de traitement du glaucome
US5212196A (en) * 1986-10-21 1993-05-18 Alcon Laboratories, Inc. Control of post-surgical intraocular pressure using clonidine derivatives
US4938970A (en) * 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5036046A (en) 1988-10-12 1991-07-30 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5051443A (en) 1988-10-12 1991-09-24 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5116868A (en) * 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
WO1991002527A1 (fr) 1989-08-21 1991-03-07 Beth Israel Hospital Association Procede et composition de traitement d'hypersensibilite cutanee, oculaire et des muqueuses, d'etats inflammatoires et hyperproliferatifs en utilisant des preparations topiques d'antagonistes de serotonine
EP0502143B1 (fr) 1990-09-07 1995-11-08 Universidad De Alicante Composition pour le traitement des douleurs oculaires
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
EP0619739A1 (fr) * 1992-10-21 1994-10-19 Alcon Laboratories, Inc. Composition destinee a irriguer les tissus intraoculaires et a maintenir la mydriase lors d'une chirurgie intraoculaire
US6117907A (en) * 1993-04-14 2000-09-12 Sher; Neal A. Topical treatment of ocular pain after corneal surgery
WO1995009004A1 (fr) * 1993-09-29 1995-04-06 Alcon Laboratories, Inc. Compositions contenant des facteurs de croissance et des agents antiplastiques
JPH08503968A (ja) 1993-09-29 1996-04-30 アルコン ラボラトリーズ，インコーポレイテッド 増殖因子と代謝拮抗物質を含有する組成物
US5624893A (en) * 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
EP0734248A1 (fr) 1993-12-17 1996-10-02 Alcon Laboratories, Inc. Solution d'irrigation intraoculaire amelioree contenat un agent anti-inflammatoire non-steroidien
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
WO1995034298A1 (fr) 1994-06-10 1995-12-21 Telor Ophthalmic Pharmaceuticals, Inc. Inhibition du myosis/de la production de mydriase peroperatoire par des anesthesiques locaux
US5523316A (en) 1994-06-23 1996-06-04 Alcon Laboratories, Inc. Intraocular irrigating solution containing agent for controlling IOP
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
WO2000023061A2 (fr) 1998-10-21 2000-04-27 Omeros Medical Systems, Inc. Solution et methode d'irrigation destinees a l'inhibition d'une douleur et d'une inflammation
US7091181B2 (en) * 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
EP1609477B1 (fr) * 1994-12-12 2011-11-09 Omeros Corporation Solution d'irrigation et utilisation de celle-ci pour inhiber périopérativement la douleur, l'inflammation et/ou les spasmes au niveau d'une structure vasculaire
KR100517210B1 (ko) 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5767105A (en) * 1995-05-03 1998-06-16 Peyman; Gholam A. Ocular solution
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6413961B1 (en) * 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6280745B1 (en) * 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
WO1998004171A1 (fr) 1996-07-26 1998-02-05 Schein Dental Equipment Co. Mecanisme d'accoudoir pour fauteuils dentaires
GB9704352D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6495598B1 (en) * 1997-04-22 2002-12-17 Ophtecs Corporation Perfusate preparation for ophthalmic operation
EP0903151A1 (fr) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Utilisation de combinations comprenant des antihistamines non sédatives et des agonistes alpha-adrenergiques pour le traitement topical du rhinitis/conjunctivitis et des symptomes du rhume et de la grippe
DE69928806T2 (de) * 1998-07-01 2006-07-20 Warner-Lambert Co. Llc (-)-pseudoephedrin als sympathomimetisches arzneimittel
DE69900207T2 (de) * 1998-07-14 2001-11-22 Alcon Laboratories, Inc. Verwendung von 11-(3-dimethylaminopropyliden)-6,11-dihydrodibenz[b,e]oxepin-2-essigsäure und deren pharmazeutisch annehmbaren salzen zur herstellung eines medikaments zur behandlung nicht-allergisch-bedingten augenentzündungen und zur prevention der okularen neovaskularisation
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AU1127700A (en) 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
AU1214900A (en) 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
ES2239466T3 (es) 1998-10-20 2005-09-16 Omeros Corporation Solucion de irrigacion y metodo de inhibicion del dolor y de la inflamacion.
AU1345000A (en) 1998-11-05 2000-05-22 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
AU3119100A (en) 1998-12-17 2000-07-03 Alcon Laboratories, Inc. Methods for the prevention and treatment of post-surgical complications
EP1202620A1 (fr) * 1999-05-14 2002-05-08 The Regents of the University of California Therapie anti-inflammatoire pour infection a mediation inflammatoire
US7273887B1 (en) * 1999-10-22 2007-09-25 Transdermatech, Inc. Topical anesthetic formulation
US6825203B2 (en) 2000-04-28 2004-11-30 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
WO2002005848A2 (fr) * 2000-07-13 2002-01-24 Pharmacia Corporation Utilisation d'inhibiteurs de cox-2 pour le traitement et la prevention de troubles oculaires a mediation cox-2
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
MXPA02012206A (es) * 2000-07-14 2003-06-04 Allergan Inc Composiciones que contienen componentes terapeuticamente activos que tienen solubilidad mejorada.
WO2002009702A2 (fr) * 2000-07-28 2002-02-07 Inspire Pharmaceuticals, Inc. Methode de reduction de la pression intraoculaire avec des derives d'indole
JP2002161032A (ja) * 2000-09-14 2002-06-04 Taisho Pharmaceut Co Ltd 粘膜適用組成物
CN1390124A (zh) * 2000-09-20 2003-01-08 永光制药有限公司 近视眼的预防、治疗药
US20020183279A1 (en) * 2001-04-18 2002-12-05 Koichiro Tanaka Pharmaceutical composition containing viscoelastic substance and medication
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
JP2006504661A (ja) 2002-07-30 2006-02-09 オメロス コーポレイション 眼科学的洗浄溶液および眼科学的洗浄方法
WO2006069213A1 (fr) 2004-12-22 2006-06-29 Schering Corporation Preparations pharmaceutiques
WO2009125218A1 (fr) 2008-04-08 2009-10-15 Fujifilm Manufacturing Europe Bv Membranes composites
CA2764477A1 (fr) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Formulations ophtalmiques, procedes pour les fabriquer et procedes pour les utiliser
WO2010141834A1 (fr) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Formulations ophtalmiques de fluticasone et procédés d'utilisation
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection

Also Published As

Publication number Publication date
AU2003261304A1 (en) 2004-02-16
JP2006504661A (ja) 2006-02-09
US20170312295A1 (en) 2017-11-02
US20160106761A1 (en) 2016-04-21
DK1534313T3 (da) 2013-02-04
WO2004010894A2 (fr) 2004-02-05
US20100311705A1 (en) 2010-12-09
US20170100412A1 (en) 2017-04-13
CY2015055I2 (el) 2016-06-22
FR15C0090I1 (fr) 2016-01-22
PT1534313E (pt) 2013-01-25
CN101327325A (zh) 2008-12-24
US20130065869A1 (en) 2013-03-14
ES2397574T3 (es) 2013-03-08
US20220175797A1 (en) 2022-06-09
NL300784I2 (nl) 2022-05-16
HK1081455A1 (en) 2006-05-19
CA2493581A1 (fr) 2004-02-05
US20130079344A1 (en) 2013-03-28
CA2866848C (fr) 2017-01-03
JP2010132696A (ja) 2010-06-17
FR15C0090I2 (fr) 2016-04-22
CN1684701B (zh) 2012-10-17
CA2493581C (fr) 2014-12-23
SI1534313T1 (sl) 2013-03-29
JP2020169205A (ja) 2020-10-15
US9585895B2 (en) 2017-03-07
US8586633B2 (en) 2013-11-19
JP2011006475A (ja) 2011-01-13
JP2022132495A (ja) 2022-09-08
JP2016014055A (ja) 2016-01-28
CA2866848A1 (fr) 2004-02-05
JP2018009033A (ja) 2018-01-18
JP2019043965A (ja) 2019-03-22
JP2022132496A (ja) 2022-09-08
US8173707B2 (en) 2012-05-08
JP2016014056A (ja) 2016-01-28
EP1534313A2 (fr) 2005-06-01
NL300784I1 (fr) 2015-12-30
US9278101B2 (en) 2016-03-08
US20140221326A1 (en) 2014-08-07
CN103143022A (zh) 2013-06-12
CY2015055I1 (el) 2016-06-22
AU2009248461B2 (en) 2013-07-18
BE2015C078I2 (fr) 2022-08-09
US20040072809A1 (en) 2004-04-15
JP2013216705A (ja) 2013-10-24
US20140235597A1 (en) 2014-08-21
EP1534313B1 (fr) 2012-10-17
CN1684701A (zh) 2005-10-19
WO2004010894A3 (fr) 2004-07-01
EP1534313A4 (fr) 2008-06-25
US9399040B2 (en) 2016-07-26
AU2009248461A1 (en) 2010-01-07
HUS1500069I1 (hu) 2016-02-29

Similar Documents

Publication Publication Date Title
LU92923I2 (fr) Une solution d'irrigation oculaire comprenant de la phényléphrine ou un sel pharmaceutiquement acceptable de celle-ci et du kétorolac ou un sel pharmaceutiquement acceptable de celui-ci
LU93320I2 (fr) Everolimus ou un sel pharmaceutiquement acceptable de celui-ci
NL300952I2 (nl) Peramivir en farmaceutisch aanvaardbare zouten daarvan
LU92397I2 (fr) Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable
LU91650I2 (fr) Saxagliptine et sels pharmaceutiquement acceptables de celle-ci, y compris l'hydrochlorure de saxagliptine - Onglyza-saxagliptin
LU91442I2 (fr) "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU91631I2 (fr) Gefitinib ou un sel pharmaceutiquement acceptable de celui-ci (IRESSA)
NO20010556L (no) Fremgangsmate for oftalmisk administrering
DE60037455D1 (de) Kinaseinhibitoren als arzneimittel
EP1239359A4 (fr) Dissipateur thermique pour une unite centrale d'un ordinateur portable
EE200200165A (et) Farmatseutiliselt toimivad sulfoonamiidi derivaadid
DZ3001A1 (fr) Sel de potassium d'oméprazole-(S).
EP2072082A3 (fr) N-(3-METHOXY-5-METHYLPYRAZIN-2-YL)-2-(4-[1,3,4-OXADIAZOL-2-YL]PHENYL)PYRIDINE-3 SULFONAMIDE comme agent analgésique
EE200200554A (et) Galantamiini või selle farmatseutiliselt sobiva soola kasutamine
DE69934902D1 (de) Medikament gegen drogenabhängigkeit
USD495789S1 (en) Shower enclosure
ITMI20032291A1 (it) Procedimento e dispositivo per l'approntamento di un combustibile
FR2797170B1 (fr) Ensemble d'aspiration
USD496438S1 (en) Shower enclosure
FR2796716B1 (fr) Tablette d'orientation
UA5691S (uk) Головний убір чоловічий відомчого призначення
FR2847782B1 (fr) Structure d'entourage d'un sommier de literie.
FR2804362B1 (fr) Coupeur d'angles doubles d'ardoises
UA5636S (uk) Плащ чоловічий
IT1311580B1 (it) Procedimento per l'elaborazione di parametri fisiologici nelleattivita' subacquee.